Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05785624 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
A Phase 2 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 286
- Enrollment target
NCT05785624 is a Phase 2 study that was terminated before completion, run by Genentech. The registered enrollment target is 286 participants.
The verdict
NCT05785624, a Phase 2 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 286 participants
- Enrollment target
Study Summary
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Cohort 1 has completed enrollment and has been closed for further enrollment. Cohort 2 is enrolling participants.
Interventions
- DRUG Placebo
- DRUG Vixarelimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2023-05-26 |
| Est. Completion | 2026-01-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05785624
The ClinicalTrials.gov registry entry for NCT05785624 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05785624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05785624 about?
NCT05785624 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease". The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of t...
What is the current status of trial NCT05785624?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 286 participants. The study started on 2023-05-26. Estimated completion is 2026-01-12.
What interventions are being tested in trial NCT05785624?
The interventions under investigation include: Placebo (DRUG), Vixarelimab (DRUG).
Who is sponsoring clinical trial NCT05785624?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.